HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report.

Abstract
Recent studies have demonstrated efficacy of bevacizumab for recurrent ovarian cancer, but few data on its use and gastrointestinal potential complications when administered as adjuvant chemotherapy after cytoreductive surgery are available. In this study, we report the first case of a rectovaginal fistula in this indication.
AuthorsElisabeth Chéreau, Dan Stefanescu, Frédéric Selle, Roman Rouzier, Emile Daraï
JournalAmerican journal of obstetrics and gynecology (Am J Obstet Gynecol) Vol. 200 Issue 1 Pg. e15-6 (Jan 2009) ISSN: 1097-6868 [Electronic] United States
PMID19121652 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (adverse effects, therapeutic use)
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Female
  • Humans
  • Middle Aged
  • Ovarian Neoplasms (drug therapy, surgery)
  • Rectovaginal Fistula (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: